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Growth hormone (GH) promotes growth in children, but is also essential for bone strength, 
body composition, metabolic factors, such as lipid proile, and maintenance of quality of 
life. The Merck KGaA (Germany) funded “360° GH in Europe” meeting, held in Lisbon, 
Portugal, in June 2016, comprised three sessions entitled “Short Stature Diagnosis and 
Referral,” “Optimizing Patient Management and Adherence,” and “Managing Transition.” 
The scientiic program covered all stages of pediatric GH treatment, and reported here 
are the outcomes of the third session of the meeting, which considered transition from 
pediatric GH treatment to teenage and young adult GH therapy. A large number of 
patients with chronic diseases, including GH deiciency, drop out of therapy during the 
transition period. Multiple factors are associated with this, such as lack of understanding 
of the disease process, insuficient knowledge of treatment options, the patient becom-
ing more independent, and requirement for interaction with a new set of health-care 
workers. Education regarding disease management and treatment options should be 
provided from an early age and right through the transition period. However, endocrine 
specialists will view the transition period differently, depending on whether they are 
pediatric endocrinologists who mainly deal with congenital diseases, in which auxology 
is important, or adult endocrinologists who are more concerned with body composition 
and metabolic factors. View points of both a pediatric and an adult endocrine specialist 
are presented, together with a case study outlining practical aspects of transition. It 
was noted in the meeting discussion that having one person to guide a patient through 
transition from an early age is important, but may be constrained by various factors such 
as inances, and options will differ by country.
Keywords: growth hormone deiciency, pediatric, adolescent, transition, personalized medicine, endocrinology
iNtrODUctiON
Growth hormone (GH) not only promotes growth in children but also develops bone strength, 
maintains lean body mass and muscle strength while reducing fat mass, normalizes metabolic factors 
such as lipid proile, and helps to maintain quality of life (1–3). Somatic development continues 
beyond adolescence, and the efects of GH on body composition and metabolism continue into 
adult life (4). However, a proportion of patients with GH deiciency identiied during childhood 
have  suicient GH secretion when stimulation tests are repeated during adolescence or early 
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adulthood (5). herefore, GH-deicient children who receive 
pediatric GH treatment require monitoring of GH status during 
adolescence, ater inal height is considered to have been achieved 
(6, 7). Algorithms have been proposed for such re-assessment of 
GH status at the transition period (7), but remain equivocal. For 
patients who are still identiied as GH deicient, continuing GH 
treatment into adulthood is required, although at a lower dose 
than during childhood, and GH treatment for adults with GH 
deiciency is an approved indication (3). While continued GH 
treatment is necessary during the time from pediatric status to 
teenage and young adult age, this transition can be a diicult 
period and requires consideration of many factors. Both pediatric 
and adult endocrine specialists need to be involved, as well as the 
patient, their family and other members of the health-care team. 
Speciic transition clinics that guide the patients through this 
period appear to help to improve various aspects of the process 
(8, 9). he present report from the third session of the 360° GH 
in Europe meeting considers aspects of transition from pediatric 
GH treatment to young adult GH treatment from diferent points 
of view of endocrine specialists. Reports from the other sessions 
on diagnosis and referral and on optimizing patient management 
are published separately (10).1
trANsitiON FrOM tHe PersPective 
OF A PeDiAtric eNDOcriNOLOGist
Transition can be deined from physiological changes during 
the period from the end of puberty to the attainment of an adult 
phenotype. he start of transition may be considered to be when 
patients reach Tanner stage 5, reported to occur at a mean age 
of 14.7 ±  2.2  years in boys or 14.0 ±  2.4  years in girls (11). It 
can also be considered to be when patients have reached their 
inal adult height, at the mean age of 16.8 ±  2.2  years in boys 
and 15.2 ± 2.0 years in girls (11). he end of transition can be 
determined from sleep chronotype when there is a switch in time 
of going to bed, which occurs at a mean of 20.9 years for males 
or 19.5 years for females (12), or from reaching peak bone mass, 
reported to occur at a mean of 23.1 years in males and 19.9 years 
in females (13). his gives the length of transition as approxi-
mately 6–9 years for boys and 5–6 years for girls, although it may 
be longer or shorter depending on multiple factors.
Alternatively, transition can be seen as the point in time when 
the patient can no longer be seen by the pediatrician and is asked 
to make the next appointment with an adult endocrinologist. 
However, focusing on a single time point is not good for a patient 
receiving GH because the transition from pediatric treatment to 
adult treatment needs to be structured. In a study of UK patients 
with congenital adrenal hyperplasia (14), which is diagnosed 
during the neonatal period, the number of patients being treated 
as adults by specialist endocrine centers was only about 10% of 
the number expected based on prevalence. Such studies indicate 
a high risk for adolescents to drop out of specialist endocrine care 
during transition to adulthood.
1Maghnie M, Labarta JI, Koledova E, Rohrer TR. Short stature diagnosis and refer-
ral. Submitted to Frontiers in Endocrinology .
Many factors inluence the drop out of patients during 
transition, including the diferences between pediatric and adult 
treatment modalities. Pediatric endocrinologists predominantly 
deal with congenital diseases and with diseases in which auxology 
is important, whereas adult endocrinologists are mostly treating 
acquired diseases and auxology is rarely important. Data analysis 
for children requires age-matched reference information, but 
reference data are constant over a wide age range in adults. Assay 
methodologies difer, with special requirements in children but 
more standardized in adults, and cutofs for endocrine tests are 
very diferent. Young children are less able to understand diseases 
and therapies, requiring parents or guardians to help them, 
whereas adults are much more involved in decision-making. 
hus, there are diferences in interactions with the patients, 
whereby pediatric endocrinologists are more likely to encourage 
patients through transition and push for interaction with adult 
endocrinologists, who may take a more wait-and-see approach.
Growth hormone replacement in children with GH deiciency 
has been shown to be efective in normalizing growth and achiev-
ing adult height within their genetic target range (15). In contrast, 
GH treatment of deiciency in adults is associated with improve-
ments in body composition, muscle strength, lipid proile, 
cardiovascular risk, and quality of life (6, 16). For patients who 
are GH deicient during adulthood, continuing GH treatment is 
important for body homeostasis. However, a majority of patients 
who require GH treatment for idiopathic or non-organic GH 
deiciency during childhood do not remain GH deicient when 
re-tested ater treatment completion (5, 6, 16). herefore, appro-
priate re-assessment is mandatory to identify patients requiring 
lifelong GH therapy.
An algorithm for management of patients during transition 
ater treatment with GH during childhood was proposed in a 
consensus statement from the European Society of Paediatric 
Endocrinology (ESPE) (7). When height velocity has decreased 
to <1.5/2.0 cm/year, GH should be discontinued for 1–3 months. 
Patients should then be grouped as either high likelihood of con-
tinuing to be GH deicient, with severe deiciency due to genetic or 
organic causes and particularly with multiple pituitary hormone 
deiciencies, or low likelihood, including patients with idiopathic 
GH deiciency that is either isolated or with only one additional 
pituitary hormone deiciency. Patients with high likelihood who 
then have an IGF-I SDS ≤−2 should restart GH; if IGF-I is >−2 
SDS then a stimulation test should be performed and GH treat-
ment should only be re-started if the stimulated peak is below the 
reference cutof. Patients with low likelihood should have both 
IGF-I assessment and a GH stimulation test, with GH re-started 
if both are low indicating continued GH deiciency; if both are 
normal then GH deiciency is excluded at that time and if the 
results are discordant then the patient should continue follow-up.
While this algorithm provided some consensus, evidence is 
lacking in many instances. he cutof for adult patients for the 
insulin tolerance stimulation test was set as <3 μg/l by ESPE and 
also the GH Research Society (GRS), but at <5 μg/l by the American 
Association of Clinical Endocrinology and the Endocrine Society. 
Similarly, diferent cutof values have been proposed for the GH 
releasing hormone–arginine stimulation test, and the GRS also 
proposed diferent cutof values depending on adult body mass 
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index. hese proposed values are for measurements in adults, but 
have not been established for patients in the transition period. 
his has led to widely varying clinical practice in establishing 
the need for continued treatment and the way that continuing 
GH deiciency is managed (17, 18). herefore, new guidelines are 
required, which should address the unresolved issues.
trANsitiON FrOM tHe PersPective 
OF AN ADULt eNDOcriNOLOGist
Transition should not be seen as a simple move from one site to 
another, but is a multi-step process during which the medical, 
psychological, social, and educational needs must all be consid-
ered (19, 20). herefore, it is necessary to work with the patient 
as a young adult, with implementation steps through transition 
organized with the active participation of the patient. As a result, 
there are many obstacles that have to be overcome, for both the 
young adult patient and the parents of the patient (21, 22).
Young adult patients generally consider that they previously 
knew about their treatment and had a close relationship with 
their physician and specialist carers. However, at transition they 
have to get to know a new physician and group of health-care 
specialists and, therefore, may feel that they are being abandoned 
by the pediatrician. Pediatric endocrinologists are likely to 
be more involved with the patient and will explain treatments 
in simple terms whereas adult endocrinologists are likely to 
explain treatment in more technical terms that the patient may 
not understand. Also, a young adult patient attending clinic 
visits with other patients who are much older, but who might 
have many more complications associated with the disease, may 
become fearful of what the future holds.
It is mandatory for physicians and other health-care staf to 
work with the parents as well as the patients (23), because parents 
will share the same fears as their children. Parents are likely to have 
been heavily involved in treatment decisions early in the course of 
a chronic disease and may have been the irst point of contact with 
the physician in regard to treatment decisions. However, parents 
now have to be able to let go and allow their child to become 
independent, although they will still feel protective.
In some countries, such as Canada and the UK, the process of 
transition involves questionnaires at diferent stages (19, 21, 23). 
he aim is to ind out what the patient knows about their disease 
and treatment options, and perspectives of the patient on future 
progress of the disease. he adult endocrinologist has to discuss 
various factors, such as autonomy, independence, and sexuality. 
Autonomy means that the patient has to think about how they can 
manage their condition, what the day-to-day practicalities are, 
and which other people need to be involved. he patient may wish 
to discuss aspects of sexuality and fertility, and adults other than 
the parents may be needed to help with this. Although perhaps 
less relevant to GH deiciency, in many chronic diseases risk of 
death is also a question that frequently requires discussion.
A therapeutic education program has been set up in endocrine 
units in Paris, France, to assist patients through transition (24). 
he program has encompassed both individual interviews and 
group sessions involving both patients and health-care special-
ists. Patients are included irrespective of their disease, although 
all are going through transition, with patients aged 16–20 years. 
Each group session involves six to eight patients for a full day and 
the patients have to describe their past experience of the disease 
and its management, as well as how they imagine the future.
he program goals were to identify new hospital structures for 
patients in transition and the means by which patients can invest 
in their own health. Following on from this, health-care pathways 
with speciic milestones are being set up for patients in transition. 
he hospital pathway involves welcoming the patient, organizing 
administrative structures, and providing therapeutic education. 
he next step is to provide links from the pediatric department to 
the adult department, which encompass all aspects of current life 
of the patient. his provides a space for the patient to discuss what 
will happen in future, for example in school and in college, and 
builds up a relationship between the patient and their health-care 
providers. he program enables use of all aspects of information 
and communication, using social media and computer applica-
tions, and can integrate the patient’s understanding and control 
of the disease during transition.
trANsitiON iN PrActice—A cAse 
stUDY
here are speciic deinitions for transition, for example it is 
deined by the Society for Adolescent Medicine as a purposeful, 
planned process that addresses the medical, psychosocial, educa-
tional, and vocational needs of adolescents and young adults with 
chronic physical and medical conditions as they move from child-
centered to adult-oriented health-care systems (20). However, 
transition can difer greatly between patients depending on their 
diagnosis, treatment journey, and capacity; thus, a patient with 
signiicant treatment-related late efects may transition at a later 
time point compared to that of a young person who has minimal 
long-term efects from their treatment. GH deiciency can arise 
from multiple etiologies and for patients who develop deiciency 
following treatment for cancer during childhood, transition is 
further complicated due to changes in health-care professionals, 
including endocrine specialists. hus, there may be more than 
one transition period for these patients.
A 21-year-old female, with a diagnosis at 5  years of age of 
rhabdomyosarcoma of the let pterygoid region, received surgery, 
chemotherapy, and radiotherapy. Scatter of the radiotherapy dose 
to her pituitary gland resulted in development of pan-hypopitui-
tarism shortly ater. She received GH treatment, which was given 
at more than 2 years ater completion of the cancer treatment, in 
accordance with approved indication guidelines, and also thyrox-
ine treatment. Adrenal insuiciency developed at 13 years of age, 
which also required treatment, while menses were regular at the 
time of reporting. Multiple specialists had been involved in the 
care, including clinical oncologists, speech and language therapists, 
surgeons, and endocrine specialists. She had profound hearing loss, 
due to platinum-based chemotherapy agents and radiotherapy, 
learning di culties that were compounded by the hearing loss, 
recurrent ear infections requiring intravenous immunoglobulin 
infusions, and sicca syndrome with di culties in swallowing.
When due to move to adult services within a large teaching 
hospital, this patient and her parents were invited to a specialist 
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evening clinic together with similar patients and their parents. A 
multidisciplinary team was involved in the clinic, and the aim was 
to discuss the new environment and to identify concerns. Issues 
discussed included whether future visits should be in a nurse-led 
or consultant-led clinic and which other specialists would be 
needed over time.
he patient had stopped GH treatment on reaching inal adult 
height, but then later presented with central adiposity and low 
energy levels. In the teenage and young adult transition clinic, 
further testing of GH status was necessary and, when GH was 
re-started, further training on administration was required and 
funding for the treatment had to be identiied. here was ongoing 
regular contact and the patient could continue communication 
with the transition team for several years while at the same time 
building a relationship with the adult endocrine team.
Within the UK, multiple sources of information on transi-
tion are provided, including policy documents from the Royal 
College of Nursing (25) and the Department of Health (26). 
Additionally, a Ready, Steady, Go program from Southampton 
University Hospital has been adopted by many UK trusts as a 
transition model (9), whereby patients start to learn about and 
be involved in transition planning from the age of 11 years, with 
information constantly updated at each consultation. his allows 
for a gradual process that gives the patient, their family and the 
current health-care team time to plan collaboratively and discuss 
their health-care needs when moving forward into adult health-
care settings. In turn, this allows identiication of keyworkers, 
strengthens relationships, and gives the patient control of their 
health-care journey.
Endocrine experts acknowledge, however, that no single model 
for transition is going to be universally successful and tailored 
care is required for patients who require continued GH treatment 
from childhood through into adulthood. A recent report by an 
expert group of health-care professionals concluded that there 
remains much to be done to ensure that the needs of adolescent 
patients with chronic endocrine conditions continue to be met 
during transition (1).
DiscUssiON sessiON
In response to a question to the audience, multiple participants 
stated that they ran transition clinics, similar to the UK experi-
ence, and that the meeting frequency depended on the number 
of patients involved. It was noted that several meetings with each 
patient were required to identify the patient’s knowledge and 
understanding about their speciic condition, to provide a full 
picture of issues that the patient has and to establish a relation-
ship with the adult endocrinology team. his needed a speciied 
person within the health-care system to manage transition and 
coordinate the treatment strategy. However, it was also noted 
that there may be problems with inancing a speciic person and 
the model may difer by country according to factors such as 
reimbursement available and skills of the personnel involved. 
In Germany, it was reported that in 2008 only 13 of 69 pedi-
atric endocrinologists responding to a structured questionnaire 
transferred GH-deicient patients in a transition clinic setting 
(8). However, communication and information transfer was 
noted to be impaired in endocrine centers without a transition 
clinic.
he process of transition should start in the pediatric setting, 
when the patient is around 11–12 years old and should involve 
sessions both with the child alone and together with the parents. 
It was suggested that one way to indicate the understanding of 
the patient was to get them to explain their condition to their 
relatives. It may also be useful to provide mentors for the patients, 
who are older patients with the same condition and who can pro-
vide explanations from a diferent perspective. While it should be 
a partnership with patients, the children and young people need 
to establish self-management. However, the transition team must 
be able to identify children who are at risk of life-threatening 
conditions, such as adrenal insuiciency (27); young patients do 
not necessarily feel ill and may not recognize risks involved in not 
managing the condition correctly.
With regard to GH treatment, it is always necessary to explain 
fully to the patient that continuing with GH is important. his 
is also important for children diagnosed as GH deicient at 
older age, even when already into the transition period (28). A 
signiicant proportion of patients who remain GH deicient at the 
end of pediatric treatment do not continue to receive GH during 
or ater transition (29). Patients need a full explanation of the 
continued efects of GH on lipids, body composition, and quality 
of life. While protocols for re-testing for GH deiciency at the time 
of transition have been published (5–7, 16), there continues to 
be discordance and the normal values for stimulation tests have 
not been fully established. In response to a question about GH 
dosing, it was suggested that dose should start at an adult level 
and then be up-titrated to normalize the IGF-I level. However, 
it should be noted that females taking concomitant oral estrogen 
may require a higher GH dose (30). An adequate dose through 
the transition period is required to attain peak bone mass, and 
it was also suggested that higher doses may be needed when 
patients get older because the response to GH may decrease.
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